<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1000">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04771845</url>
  </required_header>
  <id_info>
    <org_study_id>20-0812</org_study_id>
    <nct_id>NCT04771845</nct_id>
  </id_info>
  <brief_title>Transcranial Magnetic Stimulation in Mild Cognitive Impairment and Alzheimer Disease</brief_title>
  <official_title>Transcranial Magnetic Stimulation (TMS) in Patients With Mild Cognitive Impairment (MCI) and Alzheimer Disease (AD): A Twelve-year Retrospective Observational Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The New York Memory Services</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The New York Memory Services</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators reviewed 12 years of clinical use in an outpatient neurology setting of&#xD;
      transcranial magnetic stimulation (TMS) in patients with Alzheimer's disease (AD) and mild&#xD;
      cognitive impairment (MCI) to evaluate safety and efficacy of TMS.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators compiled demographic, clinical, and neurocognitive data on all patients who&#xD;
      had received TMS for any reason in the clinic over a 12-year period. Of 236 patients&#xD;
      receiving TMS, 59 patients with AD and 14 with MCI satisfied study criteria and were compared&#xD;
      to controls from the National Alzheimer's Coordinating Center (NACC). Neurocognitive outcomes&#xD;
      were compared between magnetic resonance imaging (MRI) and electroencephalogram (EEG)-grid&#xD;
      guided TMS in patients. Tolerability data was reviewed for all patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 1, 2008</start_date>
  <completion_date type="Actual">May 30, 2020</completion_date>
  <primary_completion_date type="Actual">May 30, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Controlled Oral Word Association Test</measure>
    <time_frame>05/01/2008-05/30/2020</time_frame>
    <description>Animal score and percentile</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Boston 30-item naming test</measure>
    <time_frame>05/01/2008-05/30/2020</time_frame>
    <description>spontaneous correct (without cues)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Boston 30-item naming test</measure>
    <time_frame>05/01/2008-05/30/2020</time_frame>
    <description>total correct (with cues)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Wechsler Adult Intelligence Scale III</measure>
    <time_frame>05/01/2008-05/30/2020</time_frame>
    <description>Digit span</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Wechsler Adult Intelligence Scale III</measure>
    <time_frame>05/01/2008-05/30/2020</time_frame>
    <description>verbal quotient score and percentile</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Wechsler Adult Intelligence Scale III</measure>
    <time_frame>05/01/2008-05/30/2020</time_frame>
    <description>performance quotient score and percentile</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Wechsler Adult Intelligence Scale III</measure>
    <time_frame>05/01/2008-05/30/2020</time_frame>
    <description>object assembly</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Wechsler Memory Scale III</measure>
    <time_frame>05/01/2008-05/30/2020</time_frame>
    <description>Immediate memory score and percentile</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Wechsler Memory Scale III</measure>
    <time_frame>05/01/2008-05/30/2020</time_frame>
    <description>Auditory delayed memory score and percentile</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Wechsler Memory Scale III</measure>
    <time_frame>05/01/2008-05/30/2020</time_frame>
    <description>Visual delayed memory score and percentile</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Buschke Selective Reminding Test, 12 item</measure>
    <time_frame>05/01/2008-05/30/2020</time_frame>
    <description>Total recall score</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Buschke Selective Reminding Test, 12 item, 15 minute</measure>
    <time_frame>05/01/2008-05/30/2020</time_frame>
    <description>Delayed recall score</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rosen Drawing Test</measure>
    <time_frame>05/01/2008-05/30/2020</time_frame>
    <description>Total score</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Processing speed</measure>
    <time_frame>05/01/2008-05/30/2020</time_frame>
    <description>Total score and percentile</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mini-mental status examination</measure>
    <time_frame>05/01/2008-05/30/2020</time_frame>
    <description>Total score</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">73</enrollment>
  <condition>Alzheimer Disease</condition>
  <condition>Mild Cognitive Impairment</condition>
  <arm_group>
    <arm_group_label>EEG-grid-guided-TMS</arm_group_label>
    <description>Patients with Alzheimer disease and mild cognitive impairment receiving TMS using electroencephalogram grid guided navigation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MRI-guided-TMS</arm_group_label>
    <description>Patients with Alzheimer disease and mild cognitive impairment receiving TMS using MRI guided navigation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NACC controls</arm_group_label>
    <description>National Alzheimer's Coordinating Center matched controls</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Transcranial Magnetic Stimulation</intervention_name>
    <description>Magnetic stimulation to alter neural activity</description>
    <arm_group_label>EEG-grid-guided-TMS</arm_group_label>
    <arm_group_label>MRI-guided-TMS</arm_group_label>
    <other_name>TMS</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with Alzheimer disease or mild cognitive impairment.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients meeting the National Institute of Neurological and Communicative Disorders&#xD;
             and Stroke and Alzheimer's Disease and Related Disorders Association (NINCDS- ADRDA)&#xD;
             criteria for possible or probable Alzheimer's disease.&#xD;
&#xD;
          -  Patients meeting the National Institute of Neurological and Communicative Disorders&#xD;
             and Stroke and Alzheimer's Disease and Related Disorders Association (NINCDS- ADRDA)&#xD;
             criteria for mild cognitive impairment.&#xD;
&#xD;
          -  Patients must have undergone at least two standardized neurocognitive batteries before&#xD;
             and after beginning TMS.&#xD;
&#xD;
          -  Patients must have received greater than or equal to five (5) TMS sessions in less&#xD;
             than one year.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        â€¢ Patients with dementias from other causes, such as Lewy Body disease.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gayatri Devi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NY Memory</affiliation>
  </overall_official>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 7, 2021</study_first_submitted>
  <study_first_submitted_qc>February 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 25, 2021</study_first_posted>
  <last_update_submitted>February 22, 2021</last_update_submitted>
  <last_update_submitted_qc>February 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The New York Memory Services</investigator_affiliation>
    <investigator_full_name>Gayatri Devi, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>TMS</keyword>
  <keyword>Transcranial Magnetic Stimulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

